Memo - Magazine of European Medical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

ASCO update —hepatocellular carcinoma and cholangiocellular carcinoma
SummaryTwo exciting phase 2 dates were presented at Asco. This results in a new phase III study for Hepatocelluar cancer that will be launched soon. With Cholangiocarcinoma there is a new substance that shows very good oberall response rates in a subgroup of patients. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 27, 2023 Category: Cancer & Oncology Source Type: research

Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction
We report a patient with HER2-positive metastatic adenocarcinoma of the GEJ who showed significant clinical and radiological benefit to HER2-directed therapy in the fifth-line therapeutic setting. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 27, 2023 Category: Cancer & Oncology Source Type: research

ASCO update —hepatocellular carcinoma and cholangiocellular carcinoma
SummaryTwo exciting phase 2 dates were presented at Asco. This results in a new phase III study for Hepatocelluar cancer that will be launched soon. With Cholangiocarcinoma there is a new substance that shows very good oberall response rates in a subgroup of patients. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 27, 2023 Category: Cancer & Oncology Source Type: research

Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction
We report a patient with HER2-positive metastatic adenocarcinoma of the GEJ who showed significant clinical and radiological benefit to HER2-directed therapy in the fifth-line therapeutic setting. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 27, 2023 Category: Cancer & Oncology Source Type: research

Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment
SummaryIn Europe, it is estimated that more than 65,000 men die each year from the consequences of advanced and metastatic prostate cancer (PCa). Currently, approximately 3.2  million European men are living with PCa. While the majority of PCa patients have favorable outcomes, the 5‑year relative survival rate for those with metastatic PCa is only 32%. Recent advances in the diagnosis of PCa have been boosted by the introduction of the prostate-specific membrane antig en (PSMA), which might identify patients with the most aggressive form of the disease. Molecular imaging with positron emission tomography (PET) targeting...
Source: Memo - Magazine of European Medical Oncology - October 19, 2023 Category: Cancer & Oncology Source Type: research

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma
SummaryThere is an unmet need for the treatment of patients with HER2-positive gastroesophageal tumors whose disease progressed on a  first-line trastuzumab-based regimen. Several prospective trials took a targeted approach and evaluated various HER2-targeted agents as second-line therapy. However, these trials failed to demonstrate a survival benefit and were negative in primary endpoints. Recently, the antibody–drug conjug ate trastuzumab deruxtecan has shown promise as a second-line treatment in patients with HER2-positive metastatic gastroesophageal tumors, with a remarkable overall response rate and a relevant...
Source: Memo - Magazine of European Medical Oncology - October 19, 2023 Category: Cancer & Oncology Source Type: research

Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment
SummaryIn Europe, it is estimated that more than 65,000 men die each year from the consequences of advanced and metastatic prostate cancer (PCa). Currently, approximately 3.2  million European men are living with PCa. While the majority of PCa patients have favorable outcomes, the 5‑year relative survival rate for those with metastatic PCa is only 32%. Recent advances in the diagnosis of PCa have been boosted by the introduction of the prostate-specific membrane antig en (PSMA), which might identify patients with the most aggressive form of the disease. Molecular imaging with positron emission tomography (PET) targeting...
Source: Memo - Magazine of European Medical Oncology - October 19, 2023 Category: Cancer & Oncology Source Type: research

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma
SummaryThere is an unmet need for the treatment of patients with HER2-positive gastroesophageal tumors whose disease progressed on a  first-line trastuzumab-based regimen. Several prospective trials took a targeted approach and evaluated various HER2-targeted agents as second-line therapy. However, these trials failed to demonstrate a survival benefit and were negative in primary endpoints. Recently, the antibody–drug conjug ate trastuzumab deruxtecan has shown promise as a second-line treatment in patients with HER2-positive metastatic gastroesophageal tumors, with a remarkable overall response rate and a relevant...
Source: Memo - Magazine of European Medical Oncology - October 19, 2023 Category: Cancer & Oncology Source Type: research

Prognostic factors of long-term survivors with unresectable pancreatic cancer: a  retrospective analysis
SummaryDespite the increasing number of patients with metastatic pancreatic adenocarcinoma (mPDAC) receiving second-line chemotherapy, little data have been reported about long-term survivors of mPDAC and prognostic factors. The study analyzes the prognostic variables of mPDAC in patients with a  survival of 10 months or longer (long-term survivors). Patients registered in an institutional database receiving chemotherapy for mPDAC were selected, and two models defined the most relevant variables at baseline and after the first cycle of chemotherapy in short- and long-term survivors. A tot al of 110 patients were include...
Source: Memo - Magazine of European Medical Oncology - October 17, 2023 Category: Cancer & Oncology Source Type: research

Cellular and humoral responses to fourth SARS-CoV-2 vaccination in a  real-life cohort of patients with cancer
This study assessed cellular and humoral responses to the fourth dose of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccines in patients with malignant diseases. Even though, clear indications of humoral, cellular, or combined response was evident in most patients undergoing active treatment, high intra- and interpatient heterogeneity in response patterns was observed. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 13, 2023 Category: Cancer & Oncology Source Type: research

Head and neck cancer revisited
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2023 Category: Cancer & Oncology Source Type: research

Long-term survival and follow-up care after cancer in Austria
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2023 Category: Cancer & Oncology Source Type: research

American Society of Hematology meeting update
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2023 Category: Cancer & Oncology Source Type: research